6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Abstract

Background Neurological and psychiatric sequelae of COVID-19 have been reported, but more data are needed to adequately assess the effects of COVID-19 on brain health. We aimed to provide robust estimates of incidence rates and relative risks of neurological and psychiatric diagnoses in patients in the 6 months following a COVID-19 diagnosis. Methods For this retrospective cohort study and time-to-event analysis, we used data obtained from the TriNetX electronic health records network (with over 81 million patients). Our primary cohort comprised patients who had a COVID-19 diagnosis; one matched control cohort included patients diagnosed with influenza, and the other matched control cohort included patients diagnosed with any respiratory tract infection including influenza in the same period. Patients with a diagnosis of COVID-19 or a positive test for SARS-CoV-2 were excluded from the control cohorts. All cohorts included patients older than 10 years who had an index event on or after Jan 20, 2020, and who were still alive on Dec 13, 2020. We estimated the incidence of 14 neurological and psychiatric outcomes in the 6 months after a confirmed diagnosis of COVID-19: intracranial haemorrhage; ischaemic stroke; parkinsonism; Guillain-Barré syndrome; nerve, nerve root, and plexus disorders; myoneural junction and muscle disease; encephalitis; dementia; psychotic, mood, and anxiety disorders (grouped and separately); substance use disorder; and insomnia. Using a Cox model, we compared incidences with those in propensity score-matched cohorts of patients with influenza or other respiratory tract infections. We investigated how these estimates were affected by COVID-19 severity, as proxied by hospitalisation, intensive therapy unit (ITU) admission, and encephalopathy (delirium and related disorders). We assessed the robustness of the differences in outcomes between cohorts by repeating the analysis in different scenarios. To provide benchmarking for the incidence and risk of neurological and psychiatric sequelae, we compared our primary cohort with four cohorts of patients diagnosed in the same period with additional index events: skin infection, urolithiasis, fracture of a large bone, and pulmonary embolism. Findings Among 236 379 patients diagnosed with COVID-19, the estimated incidence of a neurological or psychiatric diagnosis in the following 6 months was 33·62% (95% CI 33·17–34·07), with 12·84% (12·36–13·33) receiving their first such diagnosis. For patients who had been admitted to an ITU, the estimated incidence of a diagnosis was 46·42% (44·78–48·09) and for a first diagnosis was 25·79% (23·50–28·25). Regarding individual diagnoses of the study outcomes, the whole COVID-19 cohort had estimated incidences of 0·56% (0·50–0·63) for intracranial haemorrhage, 2·10% (1·97–2·23) for ischaemic stroke, 0·11% (0·08–0·14) for parkinsonism, 0·67% (0·59–0·75) for dementia, 17·39% (17·04–17·74) for anxiety disorder, and 1·40% (1·30–1·51) for psycho...

Covid-19: One in three has neurological or psychiatric condition diagnosed after covid infection, study finds

“…The rates of individual conditions also increased with severity of covid-19, the team reported in the Lancet Psychiatry 1. While 0.3% of people who had not required hospital admission had a brain haemorrhage, this rose to 2.7% among those who had been in intensive care and in 3.6% of people who had had delirium.…”

“…One in three people who have had covid-19 then have a neurological or psychiatric condition diagnosed within six months of infection—the first such diagnosis in 13% of patients—a study of US patient records has found 1…”

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

“…The estimated incidence was even higher, roughly 46%, for severely ill patients admitted to ICU. Interestingly, most diagnostic categories were more common in COVID-19 patients as compared to patients with influenza [92]. Memory impairment with or without delirium during the acute phase is a common ailment, affecting up to 44% of COVID-19 survivors [93], possibly attributed to microthrombi and cerebral structural changes in the hippocampus, insulas, and partial white matter [81,89,94].…”

Pulmonary Embolism and Acute Psychosis, a Case Report of an Outpatient with a Mild Course of COVID-19

“…Multiple case reports described development of psychiatric disorders during or post SARS-CoV-2 infection [14,15]. A recently published retrospective cohort study of 236,379 post-COVID patients showed that neurological or psychiatric diagnosis overall occurred in 34%, while 13% had no such prior history [16].…”